H.C. Wainwright lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $5 from $7 and keeps a Buy rating on the shares. The firm reduced sales forecasts for BXCL501 with the company’s strategic reprioritization focusing on clinical development and ablated commercial infrastructure.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics announces DOD grant to UNC to fund study of BXCL501
- Bioxcel Therapeutics Senior VP Wiley Transitions to Consultant
- Bioxcel Therapeutics Announces Restructuring and Leadership Changes
- BioXcel announces clinical prioritization of late-stage BXCL501 programs
- BioXcel Therapeutics announces initiation of SERENITY Phase 3 trial